US OptionsDetailed Quotes
OMCL241220P22500
- 0.05
- 0.000.00%
15min DelayClose Nov 29 13:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume11 Open Interest22.50Strike Price0.00Turnover138.83%IV51.81%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0087Delta0.0015Gamma931.80Leverage Ratio-0.0084Theta-0.0002Rho-8.14Eff Leverage0.0026Vega
Omnicell Stock Discussion
Sign in to post a comment
$Garmin (GRMN.US)$ $AtriCure (ATRC.US)$ $Vast Renewables (VSTE.US)$ $ASP Isotopes (ASPI.US)$ $Unisys (UIS.US)$ $Solidion Technology (STI.US)$ $NerdWallet (NRDS.US)$ $Xilio Therapeutics (XLO.US)$ $Cryo-Cell International (CCEL.US)$ $Omnicell (OMCL.US)$ $Reddit (RDDT.US)$ $Ensysce Biosciences (ENSC.US)$ $Tharimmune (THAR.US)$
5
1
Omnicell stock is undervalued, presenting a buying opportunity. The company's future outlook is optimistic with robust cash flows expected to increase share value. However, consider other factors like financial health before investing.
1
The company's debt situation and EBIT loss of US$31m over the last twelve months raise concerns about its financial health. The balance sheet is considered far from match-fit and the stock is deemed very risky.
Omnicell's low P/S ratio suggests limited growth. Lackluster future revenue forecasts damages its value. Investors await improved performance as current weak outlook pressures stock price.
Given the falling EPS and poor performance over the last three years, future earnings performance is being considered critical for shareholders. Potential investors are cautioned to ensure they are investing in a high-quality business amid challenges.
The sharp cut to revenue forecasts suggests that investors should temper their expectations for Omnicell, Inc. Also, analysts anticipate slower revenue growth than the wider market, which could lead to increased caution among investors.
Omnicell's recent financial troubles and its current liabilities make it a risky investment. Investors should bear in mind the firm's debt management and performance when considering its viability.
Upgrades
• $Allogene Therapeutics (ALLO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $ChampionX (CHX.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX Corp (CSX.US)$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
• $TechnipFMC (FTI.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $Norfolk Southern (NSC.US)$ : Stifel Upgrades to Buy from Hold - PT $2...
• $Allogene Therapeutics (ALLO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $ChampionX (CHX.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX Corp (CSX.US)$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
• $TechnipFMC (FTI.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $Norfolk Southern (NSC.US)$ : Stifel Upgrades to Buy from Hold - PT $2...
14
1
No comment yet
Den the Dragon :
